| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 48 |
| 1 | NIVOLUMAB | 25 |
| 2 | IPILIMUMAB | 17 |
| 3 | CARBOPLATIN | 14 |
| 4 | PACLITAXEL | 10 |
| 5 | PACLITAXEL (AIBUMIN-BOUND) | 9 |
| 6 | ATEZOLIZUMAB | 7 |
| 7 | ADALIMUMAB | 5 |
| 8 | ADALIMUMAB-AATY | 5 |
| 9 | ADALIMUMAB-ADAZ | 5 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | AVELUMAB | 3 | 0.0007 |
| 1 | WHITE PETROLATUM | 1 | 0.0007 |
| 2 | HYALURONATE SODIUM | 1 | 0.0007 |
| 3 | OMEGA-3-ACID ETHYL ESTERS | 1 | 0.0005 |
| 4 | CEMIPLIMAB-RWLC | 1 | 0.0005 |
| 5 | PEMBROLIZUMAB | 48 | 0.0004 |
| 6 | DOSTARLIMAB | 1 | 0.0004 |
| 7 | IPILIMUMAB | 17 | 0.0004 |
| 8 | ENFORTUMAB VEDOTIN | 3 | 0.0004 |
| 9 | SKIN PROTECTANT | 1 | 0.0004 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 74 | 0.0008 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 18 | 0.0004 |
| 2 | Programmed Death Ligand-1 Blocker [EPC] | 5 | 0.0002 |
| 3 | Glinide [EPC] | 1 | 0.0001 |
| 4 | Antimalarial [EPC] | 1 | 0.0001 |
| 5 | Antiprotozoal [EPC] | 1 | 0.0001 |
| 6 | Platinum-based Drug [EPC] | 17 | 0.0001 |
| 7 | Microtubule Inhibitor [EPC] | 10 | 0.0001 |
| 8 | Non-narcotic Antitussive [EPC] | 1 | 0.0001 |
| 9 | Orexin Receptor Antagonist [EPC] | 1 | 0.0001 |